Docoh
Loading...

TBPH Theravance Biopharma

News

From Benzinga Pro
Theravance Biopharma Pulls Plug On Izencitinib Crohn's Disease Trial
16 Nov 21
Biotech, News, Health Care, Small Cap, Movers, Trading Ideas, General
Expert Ratings For Theravance Biopharma
5 Nov 21
Analyst Ratings
Within the last quarter, Theravance Biopharma (NASDAQ:TBPH) has observed the following analyst ratings:
Benzinga's Top Ratings Upgrades, Downgrades For November 5, 2021
5 Nov 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
A Peek Into The Markets: US Stock Futures Mixed; All Eyes On Jobs Report
5 Nov 21
Earnings, News, Eurozone, Futures, Small Cap, Global, Pre-Market Outlook, Markets
Pre-open movers
JP Morgan Upgrades Theravance Biopharma to Neutral, Raises Price Target to $12
5 Nov 21
News, Upgrades, Price Target, Analyst Ratings
JP Morgan analyst Anupam Rama upgrades Theravance Biopharma (NASDAQ:TBPH) from Underweight to Neutral and raises the price target from $7 to $12.
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
4 Nov 21
Biotech, Earnings, News, Penny Stocks, Guidance, Offerings, Small Cap, FDA, IPOs, General
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK
12 Health Care Stocks Moving In Thursday's Pre-Market Session
4 Nov 21
Pre-Market Outlook, Markets, Movers
Theravance Biopharma Q3 Adj. EPS $(0.46) Beats $(0.55) Estimate, Sales $13.19M Miss $14.69M Estimate
3 Nov 21
Earnings, News
Theravance Biopharma (NASDAQ:TBPH) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.55) by 16.36 percent. This is a 60.34 percent increase over losses of $(1.16) per share
Earnings Scheduled For November 3, 2021
3 Nov 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion.
Theravance Biopharma Granted U.S. Patent Titled 'Neprilysin inhibitors'
21 Sep 21
News, Legal
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=5425&f=G&l=50&d=PTXT&p=109&S1=20210921&OS=20210921&RS=20210921
Analyst Ratings For Theravance Biopharma
16 Sep 21
Analyst Ratings
Analysts have provided the following ratings for Theravance Biopharma (NASDAQ:TBPH) within the last quarter:
10 Biggest Price Target Changes For Thursday
16 Sep 21
Price Target, Small Cap, Pre-Market Outlook, Analyst Ratings
Barclays boosted Adobe Inc. (NASDAQ: ADBE) price target from $660 to $740. Adobe shares rose 0.1% to $661.26 in pre-market trading.
The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study
16 Sep 21
Biotech, News, Penny Stocks, Offerings, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15)
Morgan Stanley Maintains Underweight on Theravance Biopharma, Lowers Price Target to $10
16 Sep 21
News, Price Target, Analyst Ratings
Morgan Stanley analyst Vikram Purohit maintains Theravance Biopharma (NASDAQ:TBPH) with a Underweight and lowers the price target from $14 to $10.
53 Biggest Movers From Yesterday
16 Sep 21
News, Penny Stocks, Short Sellers, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers DICE Therapeutics, Inc. (NASDAQ: DICE) shares surged 117% to settle at $36.89 on Wednesday as the company priced its IPO at $17 per share.
HC Wainwright & Co. Maintains Buy on Theravance Biopharma, Lowers Price Target to $8
16 Sep 21
News, Price Target, Analyst Ratings
HC Wainwright & Co. analyst Douglas Tsao maintains Theravance Biopharma (NASDAQ:TBPH) with a Buy and lowers the price target from $21 to $8.
SVB Leerink Maintains Outperform on Theravance Biopharma, Lowers Price Target to $10
16 Sep 21
News, Price Target, Analyst Ratings
SVB Leerink analyst Geoffrey Porges maintains Theravance Biopharma (NASDAQ:TBPH) with a Outperform and lowers the price target from $29 to $10.
12 Health Care Stocks Moving In Wednesday's Intraday Session
15 Sep 21
Intraday Update, Markets, Movers
Why Are Theravance Bio Shares Plummeting Premarket Today?
15 Sep 21
Biotech, Earnings, News, Guidance, Health Care, Small Cap, Movers, Trading Ideas, General
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
15 Sep 21
Pre-Market Outlook, Markets, Movers

Press releases

From Benzinga Pro
Theravance Biopharma to Participate in an Upcoming Investor Conference
18 Nov 21
Press Releases
DUBLIN, Nov. 18, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH), a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medicines, will participate
Theravance Biopharma, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update
3 Nov 21
Earnings, Press Releases
DUBLIN, Nov. 3, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today reported financial results for the third quarter of 2021.
Theravance Biopharma to Report Third Quarter 2021 Financial Results November 3, 2021
20 Oct 21
Press Releases
DUBLIN, Oct. 20, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH), will report its third quarter 2021 financial results and provide a business update after market close on Wednesday, November 3, 2021. An
Theravance Biopharma, Inc. Announces Strategic Actions to Focus on Respiratory Disease Portfolio
15 Sep 21
Press Releases
DUBLIN and SOUTH SAN FRANCISCO, Calif., Sept. 15, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today announced strategic actions to focus on
Theravance Biopharma, Inc. Announces Top-line Results from a Phase 3 Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension
15 Sep 21
Press Releases
DUBLIN and SOUTH SAN FRANCISCO, Calif., Sept, 15, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH), a diversified biopharmaceutical company primarily